Nkarta, Inc.
Natural killer cell therapies for autoimmune disease treatment
- Sector
- Biotech
- Headquarters
- SOUTH SAN FRANCISCO, CA
- Latest Form D
- $43.9M, Sep 2019
- Total capital
- $43.9M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $43.9M
- 1 Form D · last Sep 2019
- 86 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 8
- 32 pending · first 2021
- Rank in peer group#196 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$43.9M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#196 · top 14%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Ali BehbahaniDirectorNamed in SEC Form D filings
- Fouad AzzamDirectorNamed in SEC Form D filings
- Jill CarrollDirectorNamed in SEC Form D filings
- Matthew PlunkettExecutive OfficerNamed in SEC Form D filings
- Michael DybbsDirectorNamed in SEC Form D filings
- Paul HastingsExecutive Officer, DirectorNamed in SEC Form D filings
Show all 7 people
- Tiba AynechiDirectorNamed in SEC Form D filings
What it has protected
USPTO · 8 granted of 40- PendingGenetic Editing Of Target Genes To Enhance Natural Killer Cell FunctionUSPTOApplication 18997909
- PendingCompositions For Treatment Of Autoimmune DiseasesUSPTOApplication 19353081
- GrantedMethods For The Simultaneous Expansion Of Multiple Immune Cell Types, Related Compositions And Uses Of Same In Cancer ImmunotherapyUSPTOUS 12,590,148
Show all 40 patent records
- Genetic Editing Of Target Genes To Enhance Natural Killer Cell FunctionMay 28, 2026 · Application 18997909Pending
- Compositions For Treatment Of Autoimmune DiseasesMay 28, 2026 · Application 19353081Pending
- Methods For The Simultaneous Expansion Of Multiple Immune Cell Types, Related Compositions And Uses Of Same In Cancer ImmunotherapyMar 31, 2026 · US 12,590,148Granted
- Methods Of Treating Primary Liver Tumors With Natural Killer Cells Expressing A Cytotoxic Receptor ComplexMar 12, 2026 · Application 19325376Pending
- Dosing Regimens For CD19-DIRECTED Cancer ImmunotherapyFeb 26, 2026 · Application 18877116Pending
- Engineered Immune Cells With Enhanced Potency And Uses Of Same In ImmunotherapyJan 1, 2026 · Application 18729489Pending
- Immune Cells Comprising Truncated NKG2D Chimeric ReceptorsDec 25, 2025 · Application 19227964Pending
- Selection Of Optimal Cell Donors And Methods And Compositions For Enhanced Expansion And Cytotoxicity Of Donor CellsNov 6, 2025 · Application 18291826Pending
- Bcma-directed Cellular Immunotherapy Compositions And MethodsOct 16, 2025 · Application 18578164Pending
- CD19-DIRECTED Chimeric Antigen Receptors And Uses Thereof In ImmunotherapySep 25, 2025 · Application 19080060Pending
- CD19-DIRECTED Chimeric Antigen Receptors And Uses Thereof In ImmunotherapyAug 26, 2025 · US 12,398,187Granted
- Immune Cells Comprising Truncated NKG2D Chimeric ReceptorsJul 8, 2025 · US 12,351,617Granted
- Dosing Regimens For Cancer ImmunotherapyMar 6, 2025 · Application 18559514Pending
- Methods For Treatment Of Autoimmune DiseasesOct 31, 2024 · Application 18626710Pending
- Genetically Modified Natural Killer Cells For CD70-DIRECTED Cancer ImmunotherapyOct 31, 2024 · Application 18657550Pending
- Methods Of Engineering Immune Cells For Enhanced Potency And Persistence And Uses Of Engineered Cells In ImmunotherapyOct 10, 2024 · Application 18255222Pending
- Genetically Modified Natural Killer Cells For CD70-DIRECTED Cancer ImmunotherapyJun 18, 2024 · US 12,012,458Granted
- Enhanced Expansion And Cytotoxicity Of Engineered Natural Killer Cells And Uses ThereofAug 24, 2023 · Application 18024012Pending
- Bcma-directed Cellular Immunotherapy Compositions And MethodsJan 26, 2023 · Application 17758116Pending
- Methods And Compositions For Enhanced Expansion And Cytotoxicity Of Natural Killer CellsDec 29, 2022 · Application 17628105Pending
- Combinations Of Engineered Natural Killer Cells And Engineered T Cells For ImmunotherapyJul 28, 2022 · Application 17596166Pending
- Truncated NKG2D Chimeric Receptors And Uses Thereof In Natural Killer Cell ImmunotherapyJun 21, 2022 · US 11,365,236Granted
- CD19-DIRECTED Chimeric Antigen Receptors And Uses Thereof In ImmunotherapyFeb 22, 2022 · US 11,253,547Granted
- Methods Of Treating Primary Liver Tumors With Natural Killer Cells Expressing A Cytotoxic Receptor ComplexNov 4, 2021 · Application 17274022Pending
- Cancer Immunotherapy Using CD19-DIRECTED Chimeric Antigen ReceptorsOct 26, 2021 · US 11,154,575Granted
- Immune Cells Engineered To Express CD19-DIRECTED Chimeric Antigen Receptors And Uses Thereof In ImmunotherapyOct 12, 2021 · US 11,141,436Granted
- Methods For Treatment Of Autoimmune DiseasesApplication 63567812Pending
- Transmembrane Proteins And Related Compositions And UsesApplication 63733187Pending
- Methods For Treatment Using CD19-DIRECTED ImmunotherapiesApplication 63567795Pending
- Transmembrane Proteins And Related Compositions And UsesApplication 63551941Pending
- Antibodies And Chimeric Antigen Receptors Specific For CD38Application PCTUS2024021673Pending
- Modulation Of Immune Cell Gene ExpressionApplication 63735015Pending
- Compositions For Treatment Of Autoimmune DiseasesApplication 63789274Pending
- Dosing Regimens For Combination TherapiesApplication 19128533Pending
- Dosing Regimens For Treatment Of CancerApplication 19493492Pending
- Methods For Treatment Of Autoimmune DiseasesApplication PCTUS2024023051Pending
- Modulation Of Immune Cell Gene ExpressionApplication 63745989Pending
- Compositions For Treatment Of Autoimmune DiseasesApplication PCTUS2025050028Pending
- Methods For Treatment Using CD19-DIRECTED ImmunotherapiesApplication 63574450Pending
- Methods For Treatment Using CD19-DIRECTED ImmunotherapiesApplication PCTUS2024035555Pending
Related companies, and why
- SynlogicSimilar federal contract value in Biotech · null in contracts
- Akero TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Pionyr ImmunotherapeuticsSimilar federal contract value in Biotech · null in contracts
- GLOBEIMMUNE INCSimilar federal contract value in Biotech · null in contracts
- Liquid BioScience, Inc.Similar federal contract value in Biotech · null in contracts
- Earli Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .